Difference between revisions of "Extramammary Paget disease"

Jump to navigation Jump to search
Line 112: Line 112:
*Differentiation markers GATA - apocrine and urothelial; p63 - squamous, CDX2 - colorectal
*Differentiation markers GATA - apocrine and urothelial; p63 - squamous, CDX2 - colorectal


Notice that a CK20 negative urothelial origin EMPD will show the same immunoprofile as a primary cutaneous EMPD.
*Notice that a CK20 negative urothelial origin EMPD will show the same immunoprofile as a primary cutaneous EMPD.
Notice that you do not need to consider mammary Paget disease or Toker cells in your ddx.
*Notice that you do not need to include markers for mammary Paget disease or Toker cells.
You can not rely on any one marker - a panel is required
You can not rely on any one marker - a panel is required
**Do not rely on CK7 alone as CK7 may be positive in pagetoid squamous cell carcinoma in situ or extramammary Paget disease <ref>{{Cite journal  | last1 = Raju | first1 = RR. | last2 = Goldblum | first2 = JR. | last3 = Hart | first3 = WR. | title = Pagetoid squamous cell carcinoma in situ (pagetoid Bowen's disease) of the external genitalia. | journal = Int J Gynecol Pathol | volume = 22 | issue = 2 | pages = 127-35 | month = Apr | year = 2003 | doi =  | PMID = 12649666 }}</ref>
**Do not rely on CK7 alone as CK7 may be positive in pagetoid squamous cell carcinoma in situ or extramammary Paget disease <ref>{{Cite journal  | last1 = Raju | first1 = RR. | last2 = Goldblum | first2 = JR. | last3 = Hart | first3 = WR. | title = Pagetoid squamous cell carcinoma in situ (pagetoid Bowen's disease) of the external genitalia. | journal = Int J Gynecol Pathol | volume = 22 | issue = 2 | pages = 127-35 | month = Apr | year = 2003 | doi =  | PMID = 12649666 }}</ref>
653

edits

Navigation menu